



1647

PATENT APPLICATION  
File No: 97-75

TECH CENTER 1600/2900

MAR 21 2002

RECEIVED

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of : Paul O. Sheppard, Stephen R. Jaspers, Zeren Gao  
Serial No. : 10/011,859  
Group Art Unit :  
Examiner :  
Filed : November 5, 2001  
For : CONNECTIVE TISSUE GROWTH FACTOR HOMOLOGS

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Commissioner for Patents  
Washington, DC 20231

Sir:


I hereby certify that the attached correspondence, comprising:

1. Information Disclosure Statement
2. PTO-1449 Form (2 sheets)
3. 19 References
4. Return Postcard

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
Washington, DC 20231

on March 7, 2002.

  
\_\_\_\_\_  
Amy Toman



#4

PATENT APPLICATION  
File No: 97-75C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Paul O. Sheppard, Stephen R. Jaspers, Zeren Gao  
Serial No. : 10/011,859  
Group Art Unit :  
Examiner :  
Filed : November 5, 2001  
For : CONNECTIVE TISSUE GROWTH FACTOR HOMOLOGS  
Date Submitted : March 7, 2002

RECEIVED  
MAR 21 2002  
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the examination of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

In accordance with 37 C.F.R. 1.97, the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been conducted, nor shall it be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

The references are listed in PTO form 1449 which is in accordance with the requirements of M.P.E.P. 609. Applicants believe that their invention as claimed is patentable over the references. It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

Respectfully submitted,

Deborah A. Sawislak  
Registration No. 37,438

**FORM PTO 1449**  
(REV 2-32)

**U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE**

File No. 97-75C1

Serial No.  
10/011,859


INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant(s):  
Paul O. Sheppard, Stephen R. Jasper  
Zeren Gao

Filing Date:  
November 5, 2001

Group:

(Use several sheets if necessary)



TECH CENTER 1600/2900  
MAR 21 2002

RECEIVED

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	99/21998	5/6/99	PCT		

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)**

	A2	LIFESEQ™ Clone Information Results (INC555067), Incyte Pharmaceuticals, Inc., 1995.
	A3	LIFESEQ™ Clone Information Results (INC2509339), Incyte Pharmaceuticals, Inc., 1997.
	A4	LIFESEQ™ Clone Information Results (INC3208053), Incyte Pharmaceuticals, Inc., 1997.
	A5	LIFESEQ™ Clone Information Results (INC3941821), Incyte Pharmaceuticals, Inc., 1997.
	A6	LIFESEQ™ Clone Information Results (INC3036490), Incyte Pharmaceuticals, Inc., 1998.
	A7	Strausberg, Cancer Genome Anatomy Project, Genbank Acc. No. AA592984, 1997.
	A8	Strausberg, Cancer Genome Anatomy Project, Genbank Acc. No. AA897322, 1997.
	A9	Marra et al., WashU-HHMI Mouse EST Project, Genbank Acc. No. AA200958, 1996.
	A10	Marra et al., WashU-HHMI Mouse EST Project, Genbank Acc. No. AA764003, 1996.
	A11	Marra et al., WashU-HHMI Mouse EST Project, Genbank Acc. No. AA840452, 1996.
	A12	LIFESEQ™ Library Information Results (BRAIUNT01), Incyte Pharmaceuticals, Inc., date unknown.
	A13	LIFESEQ™ Library Information Results (SCORNOT04), Incyte Pharmaceuticals, Inc., date unknown.

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>FORM PTO 1449</b> (REV 2-32)		<b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>		File No. 97-75C1	Serial No. 10/011,859
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)				Applicant(s): Paul O. Sheppard, Stephen R. Jasper, Zeren Gao	
				Filing Date: November 5, 2001	Group:

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)**

[illegible]

Examiner	Date considered
----------	-----------------

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

MAR 21 2002

TECH CENTER 1600/2900